Aisling Capital LLC - Q4 2015 holdings

$580 Million is the total value of Aisling Capital LLC's 22 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 0.0% .

 Value Shares↓ Weighting
CEMP  CEMPRA INC$68,270,000
+11.8%
2,193,0600.0%11.77%
+9.7%
ESPR  ESPERION THERAPEUTICS INC.$36,442,000
-5.6%
1,637,1250.0%6.28%
-7.4%
ADMA  ADMA BIOLOGICS INC$29,118,000
-3.5%
3,608,1710.0%5.02%
-5.3%
AGRX  AGILE THERAPEUTICS INC"$29,122,000
+44.8%
2,983,7970.0%5.02%
+42.0%
VSAR  VERSARTIS INC$28,244,000
+7.5%
2,279,5680.0%4.87%
+5.4%
TRXC  TRANSENTERIX INC.$20,673,000
+9.7%
8,335,8190.0%3.56%
+7.6%
CTLT  CATALENT INC$17,913,000
+3.0%
715,6730.0%3.09%
+1.0%
PRTK  PARATEK PHARMACEUTICALS INC$12,950,000
-0.2%
682,6800.0%2.23%
-2.1%
XENT  INTERSECT ENT INC$7,875,000
-3.8%
350,0000.0%1.36%
-5.7%
PTX  PERNIX THERAPEUTICS HLDGS IN$5,930,000
-6.6%
2,010,0000.0%1.02%
-8.4%
 PERNIX THERAPEUTICS HLDGS INCdebt$1,450,000
-19.8%
2,500,0000.0%0.25%
-21.4%
EVAR  LOMBARD MED INC$1,197,000
-62.2%
886,3630.0%0.21%
-62.9%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2016-02-10
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
TRANSENTERIX INC.22Q3 201912.1%
CHIMERIX INC.21Q4 201819.4%
ADMA BIOLOGICS INC.20Q3 201935.5%
LOXO ONCOLOGY INC.18Q4 201880.9%
AIMMUNE THERAPEUTICS INC.17Q3 201968.7%
CIDARA THERAPEUTICS INC.17Q3 20194.1%
AGILE THERAPEUTICS INC.16Q1 20185.5%
ZELTIQ AESTHETICS INC14Q3 201716.3%
ESPERION THERAPEUTICS INC NE14Q3 201724.9%
VERSARTIS INC13Q2 201716.2%

View Aisling Capital LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2019-11-13
13F-HR2019-08-08
13F-HR2019-05-07
13F-HR2019-02-11
13F-HR2018-11-05
13F-HR2018-08-13
13F-HR2018-05-14
13F-HR2018-02-07
13F-HR2017-11-09
13F-HR2017-08-14

View Aisling Capital LLC's complete filings history.

Compare quarters

Export Aisling Capital LLC's holdings